Belite Bio Inc American Depositary Shares BLTE · Stock Open Belite Bio Inc American Depositary Shares in new tab
Belite Bio Inc American Depositary Shares Analysis (BLTE)
Is Belite Bio Inc American Depositary Shares a good investment? Belite Bio Inc American Depositary Shares (BLTE) is currently trading at 154.65 USD. Market analysts have a consensus price target of 56.75 USD. This suggests the asset is currently trading above analyst expectations.
Earnings Schedule: Belite Bio Inc American Depositary Shares is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -0.96.
Investor FAQ
Does Belite Bio Inc American Depositary Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is Belite Bio Inc American Depositary Shares?
Belite Bio Inc American Depositary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -1.23.
Company Profile
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Community Discussion